While anti-tumor medication helps to restrict tumor proliferation, it can simultaneously downregulate insulin-mediated glucose disposal to skeletal muscle and promote hyperglycemia/hyperinsulinemia [46, 47, 54]. This evidence concerns the gene INS and hyperinsulinism.